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Abstract
Reelin is a signaling protein increasingly associated with the pathogenesis of Alzheimer’s disease that relevantly
modulates tau phosphorylation. We have previously demonstrated that β-amyloid peptide (Aβ) alters reelin
expression. We have now attempted to determine whether abnormal reelin triggered by Aβ will result in signaling
malfunction, contributing to the pathogenic process. Here, we show that reelin forms induced by β-amyloid are less
capable of down-regulating tau phosphorylation via disabled-1 and GSK3β kinase. We also demonstrate that the
scaffold protein 14-3-3 that increases tau phosphorylation by modulating GSK3β activity, is up-regulated during
defective reelin signaling. Binding of reelin to its receptor, mainly ApoER2 in the brain, relays the signal into the cell.
We associate the impaired reelin signaling with inefficiency of reelin in forming active homodimers and decreased
ability to bind efficiently to its receptor, ApoER2. More remarkably, reelin from Alzheimer cortex shows a tendency to
form large complexes instead of homodimers, the active form for signaling. Our results suggest that reelin expression
is altered by Aβ leading to impaired reelin signaling.
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Introduction
Increasing evidence suggests that Reelin expression is
altered in the Alzheimer’s disease (AD) brain. Reelin is a
signaling protein which modulates synaptic function and
plasticity in the mature brain, and its signaling cascade can
control tau phosphorylation [1,2]. The binding of Reelin to the
transmembrane liporeceptors, apolipoprotein receptor 2
(ApoER2) or the very-low-density liporeceptor (VLDLR), relays
the signal into the cell via the adapter Dab1 (disabled-1),
initiating a cascade of intracytoplasmic events that ends with
limited phosphorylation of the microtubule-associated tau
protein, via inhibition of Glycogen synthase kinase 3 beta
(GSK3β) activity; for a review, see [3].
Pathological hyperphosphorylation and aggregation of tau,
concurrent with extracellular deposits of the β-amyloid protein
(Aβ), are features of AD. Lack of Reelin is associated with
increased tau phosphorylation [4], and mutations that prevent
the Reelin-dependent induction of Dab1 tyrosine
phosphorylation also cause tau hyperphosphorylation [5].
Reduced Reelin expression has been shown to accelerate tau
pathology in transgenic AD mice [6]. Accordingly, Reelin
depletion has been reported in affected brain areas of AD
subjects and β-amyloid transgenic mouse models [7,8].
However, ours and other studies have demonstrated an
increase in Reelin levels in the AD brain and in mice over-
expressing Aβ [9–12]. This could be induced by β-amyloid as
Aβ treatment elevates Reelin levels [11]. Increase in
expression of the Reelin gene has been confirmed in two
different AD cohorts [10,11], and has been associated with the
specific vulnerability of neurons to AD [13]. We also have
previously demonstrated that Aβ alters Reelin glycosylation,
resulting in a glycosylation pattern similar to that of Reelin from
cortex and cerebrospinal fluid (CSF) of AD patients [10,11].
The physiological consequences of alterations in Reelin
expression are still unclear.
We have now attempted to determine whether abnormal
Reelin triggered by Aβ treatment will result in signaling
malfunction. In a cellular system, we study if an altered form of
Reelin affects the Reelin signaling pathway, including Dab1,
GSK3β and ultimately tau phosphorylation. We also illustrate
that Aβ-altered Reelin glycoforms alters intracellular levels of
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the scaffold protein 14-3-3, a protein which promotes
phosphorylated GSK3β to remain active, suggesting that this
mechanism is also affected by impaired Reelin signaling.
Finally, we investigated whether abnormal Reelin fails to bind
ApoER2, the main brain receptor, and to form efficient
signaling homodimers. We further examined the ability of
Reelin species present in the AD brain to form homodimers.
Material and Methods
Collection of human brain samples
This study was approved by the ethics committee of the
Miguel Hernandez University and was carried out in
accordance with the Declaration of Helsinki. Brain samples
were obtained from the UIPA neurological tissue bank (Unidad
de Investigación Proyecto Alzheimer, Madrid, Spain). After
neuropathological examination, sporadic AD cases were
categorized as stages V-VI of Braak and Braak (five cases; 66±
7 years). Samples from ND individuals (non-demented control
subjects; five cases; 73± 2 years) corresponded to cases with
no clinical dementia and no evidence of brain pathology. The
mean postmortem interval of the tissue was 6 h, with no
significant difference between each group of samples.
Preparation of human brain samples
Samples (0.2 g) of human frontal cortex were homogenized
(10% w/v) in 50 mM Tris-HCl, pH 7.4 / 150 mM NaCl/0.5%
Triton X-100/0.5% Nonidet P-40 containing a cocktail of
proteinase inhibitors (10,11). The homogenates were sonicated
and centrifuged at 20,000×g at 4° C for 20 min; the supernatant
was collected and frozen at -80° C. When samples were
prepared for native-blue electrophoresis, the solubilization
buffer contained 25 mM Bis-Tris pH 7.0, 0.5% n-dodecyl-beta
D-maltoside (DDM), 20% glycerol.
Cell cultures
SH-SY5Y cells were seeded in 75cm2 flasks at a density of
7×105 cells/flask and cultured in DMEM supplemented with
Glutamax (Invitrogen), 10% heat-inactivated fetal calf serum,
100 U/mL penicillin and 100 µg/mL streptomycin. To
differentiate the cells, serum was reduced to 3% and 10 µM all-
trans-retinoic acid (Sigma) was added for 5 consecutive days.
Following this, serum was further reduced to 0.5% and 50
ng/ml of brain-derived neurotrophic factor (BDNF; Sigma) was
added for the remaining culture period. Suspensions of β-
amyloid 1-42 (Aβ42) or scrambled control peptide (Aβsc;
AIAEGDSHVLKEGAYMEIFDVQGHVFGGKIFRVVDLGSHNVA
) (both from American Peptide Company Inc.) dissolved in
sterilized distilled water at a concentration of 1 mg/mL, were
added one day after BDNF incubation at a final concentration
of 10 µM, and this treatment was repeated 2 days later. The
cell medium was no longer changed. Cells were cultured in
presence of Aβ42 or Aβsc for 4 consecutive days. In some
experiments, cells were treated with a lower dose of 1 µM
Aβ42. Alternatively, cells were also treated for 24 h with 100
µM of deoxymannojirimycin (DMJ, Tocris) instead of Aβ.
SH-SY5Y cells cultured in 96-well plates and treated as
previously described, were assessed for cell viability using the
tetrazolium assay (MTS; CellTiter 96® AQueous Assay,
Promega) according to the manufacturer’s instructions.
For primary cortical neuron cultures, cortical lobes from
E16.5 mice embryos were trypsinized and dissociated in
Hanks’ balanced salt solution (Life Technologies). Neurons
were plated onto 35-mm dishes (1.3×106 cells/dish) and
maintained in Neurobasal medium (Invitrogen) containing B27
supplements (GIBCO BRL), 100 IU/ml penicillin, 100 µg/ml
streptomycin and 2 mM glutamine. After 7 days, cortical
neurons were treated with Reelin for 1 h. Cells were washed
with Hank’s balanced salt solution (HBSS, Life Technologies)
and scraped into 6× SDS-PAGE sample buffer, heated at 100°
C for 5 min and cell lysates stored at -80° C.
Reelin preparation
Medium from untransfected SH-SY5Y cells treated with (or
without) Aβ was collected and centrifuged at 1,500×g for 5 min
(this pellet was reserved for Western blotting analysis). The
supernatant was filtered and concentrated using a Microcon
filter with a 100 kDa cutoff (Millipore) to obtain enriched Reelin
supernatants. Alternatively, in some cell media Aβ was
removed by immunoprecipitation with the anti-Aβ polyclonal
antibody 6E10 (Covance). Magnetic beads (PureProteome,
Millipore) were coupled to 6E10 following manufacturer’s
instructions. The 6E10-beads were incubated with medium
from SH-SY5Y cells treated with (or without) Aβ for 4 h at 4° C,
then centrifuged at 500×g and the supernatant fraction re-
incubated with fresh magnetic 6E10-beads at the same
conditions. Immunocomplexes were separated by
centrifugation and Aβ content was determined in the unbound
fraction. These two successive incubations with the anti-Aβ
beads ensured that most of the peptide in the samples was
removed.
Cell adhesion assay
Six-well plates were treated with nitrocellulose dissolved in
methanol and left to dry. Then, wells were coated with equal
amounts of Cont-Reelin or Aβ-Reelin, and left overnight at 37°
C. SH-SY5Y cells were plated and, after 2 h incubation, cells
were washed extensively with Phosphate buffered saline. The
remaining cells were counted. In some experiments Cont-
Reelin was pre-incubated with the CR50 antibodies (20 µg/mL)
for 1 h before coating.
Western Blotting and antibodies
For Reelin detection brain extracts (30 µg) or SH-SY5Y
supernatant samples (30 µl) were boiled for 3 min, and then
resolved on 6% SDS-polyacrylamide gels (SDS-PAGE).
Proteins were blotted onto nitrocellulose membranes and
incubated with the anti-Reelin 142 antibody (1:500 dilution,
Merck Millipore). Electrophoresis was allowed to proceed at a
voltage that prevented excessive heat generation that affects
Reelin detection [10,14]. As Reelin content varied broadly
between different brain extracts, preliminary analysis was
performed to ensure that the immunodetection signals lie within
a linear range. For detection of other proteins, extracts from
Aβ Impairs Reelin Signaling
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cultured neurons (15-25 µl) were boiled for 5 min in SDS-PAGE
sample buffer. Levels of total tau (1:10000 dilution;
DakoCytomation) and phospho-tau (AT8, Ser202, Innogenetics,
at 1:2000 dilution; PHF13, Ser396, Abcam, at 1:2000 dilution)
were detected by Western blot following resolution on 10%
SDS-PAGE. Total GSK-3 (1:2000 dilution; Abcam), GSK3ser9
(1:2000 dilution; Abcam) and Dab1 (1:2000 dilution; Exalpha
Biologicals, Inc) were resolved on 7.5% SDS-PAGE.
PhosphoBlocker (5% from Cell Biolabs, Inc) was used to block
membranes for phosphorylated proteins, and the 4G10
Platinum anti-phosphotyrosine antibody (1:2000 dilution; Merck
Millipore) was used to detect phosphorylated tyrosines. The
immunoreactivity of phosphorylated isoforms of Dab1, GSK-3
and tau were normalized to total levels of the respective
protein; α-tubulin (Sigma-Aldrich) also served as a loading
control. Aβ peptide from the supernatant of cells were analyzed
by 10% Tris-tricine SDS-PAGE and detected with the anti-
human Aβ antibody 4G8 (1:4000 dilution; Covance Research).
For blue-native gel electrophoresis, samples were not boiled
and electrophoresis was performed as previously described
[15], using NativeMark™ Unstained Protein Standards (Life
Techologies) as molecular weight marker. The signal was
visualized by ECL (GE Healthcare Life Science) and analyzed
using Science Lab Image Gauge v 3.0 software (Fujifilm).
The anti-Reelin CR50 antibody (MBL Int. Corp.) was used at
15µl/ml and incubated for 1 h with media containing Reelin to
neutralize its function.
Sucrose gradients
Reelin complexes were fractionated by ultracentrifugation at
150,000×g in a continuous sucrose gradient (5-20% w/v) for 18
hr at 4° C in a Beckman SW41 rotor. Brain extracts (~700 µl)
were carefully loaded onto the top of the gradient containing 10
ml of 0.5 M NaCl, 50 mM MgCl2 and 0.5% (w/v) Triton X-100, in
50 mM Tris-HCl (pH 7.4). After centrifugation, the bottom of the
tubes were punctured and 30-32 fractions were collected.
Enzymes markers of known sedimentation coefficient (β-
galactosidase, catalase and alkaline phosphatase) were used
in the gradients to determine the approximate sedimentation
coefficients.
Lectin binding analysis of Reelin
Aliquots of brain extracts and SH-SY5Y cell medium were
mixed with 40 µl of immobilized lectins Con A (lectin from
Canavalia ensiformis) and LCA (lectin from Lens culinaris
agglutinin, both from Sigma-Aldrich) that recognize mannosyl
residues, with each lectin having subtle differences in their
structure. Con A binds mannose, while LCA also interacts with
α-mannosyl residues of N-linked sugar chains while also
requiring the presence of a fucose residue bound to the C-6
hydroxyl group of the GlcNAc at the reducing end for strong
binding [16]. The Reelin-lectin mixture was incubated overnight
at 4° C with gentle mixing; unbound Reelin was separated by
centrifugation and examined by Western blotting.
ApoER2-binding assay
Extracts from HEK-293 cells transfected with full-length
mouse ApoER2 tagged with EGFP (gift from J. Nimpf) were
incubated with an anti-GFP antibody immobilised in Sepharose
(Abcam) for 4 h. Immobilized ApoER2-GFP was then incubated
overnight with Reelin-enriched supernatants from Aβ-treated
SH-SY5Y cells. Bound proteins were washed and both bound
and unbound fractions were subject to Western blot analysis.
Statistical analysis
Data are expressed as means ± SEM. Data were analyzed
using SigmaStat (Version 2.0; SPSS Inc.) by Student’s t-test
(two tailed) or by one-way analysis of variance (ANOVA),
followed by Tukey test for pair-wise comparisons. Statistical
significance was designated as p < 0.05.
Results
Abnormal Aβ-Reelin fails to reduce tau
phosphorylation
To assess the ability of altered Reelin expressed in presence
of β-amyloid to activate its signaling cascade we used Reelin
from an in vitro cell model. We have previously described that
treatment of SH-SY5Y neuroblastoma cells with Aβ42
influences Reelin expression and induces changes in Reelin
glycosylation that resemble Reelin glycoforms observed in AD
brain [11]. Secreted Reelin was collected from untransfected
SH-SY5Y cells treated without (Cont-Reelin) or with Aβ42 (Aβ-
Reelin). Most of the soluble Aβ42 oligomers were removed
during the centrifugation and posterior filtration process, and
only traces of the peptide were resolved in fractions of the
Reelin enriched supernatant, after SDS-PAGE and Western
blotting (Figure S1A). Alternatively, Aβ was further depleted by
two cycles of immunoprecipitation with the antibody 6E10; as a
result of this, traces of Aβ were undetectable (Figure S1A). To
avoid differences in the amount of Reelin obtained from SH-
SY5Y-treated cells, the 420 kDa band from Cont-Reelin and
Aβ-Reelin was quantified by Western blots and equalized. We
first corroborated that secreted Cont-Reelin and Aβ-Reelin
display differences in glycosylation and have different binding
affinities to Con A and LCA, as we previously found in Reelin
from human brain extracts [11]. Alteration in Reelin
glycosylation was demonstrated by a lectin-binding assay
based on lectins that recognize mannosyl residues, but which
have subtle differences in their structure [16]. Western blot
analysis of the Con A unbound-protein fraction indicated higher
affinity for secreted Cont-Reelin (a low Reelin immunoreactivity
in the unbound fraction indicates high affinity for the lectin) than
for Aβ-Reelin, whereas Aβ-Reelin displays higher affinity to
LCA (Figure S1B).
Then, we determined if the changes in Reelin glycosylation
by Aβ alter Reelin capacity to control tau phosphorylation.
Mouse primary cortical cultures were treated with similar
amounts of enriched Cont-Reelin or Aβ-Reelin preparations.
Cont-Reelin decreases phosphorylation of tau, compared to
non-treated neurons, whereas neurons treated with Aβ-Reelin
leads to an increase in tau phosphorylation, estimated by the
anti-phospho-tau antibodies AT8 (Ser202) and PHF13 (Ser396,
an epitope phosphorylated by GSK3β, see 17), (Figure 1). Aβ-
Reelin obtained from SH-SY5Y cells treated with 1 µM Aβ42
also fails to reduce tau phosphorylation. Moreover, Aβ-Reelin
Aβ Impairs Reelin Signaling
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from SH-SY5Y cells treated with 10 µM Aβ42 and obtained
after immunodepletion of the Aβ peptide, also increases tau
phosphorylation (not shown). The changes in tau
phosphorylation driven by treatment with Aβsc were similar to
those detected in cells treated with Cont-Reelin. When neurons
were treated with Reelin in the presence of the CR50, an anti-
Reelin antibody which neutralizes Reelin [18,19], the
phosphorylation levels of tau increases, confirming that the
observed effects are Reelin dependent (Figure 1).
However, we cannot discard that undetectable traces of Aβ
could affect directly tau phosphorylation in our cell system. To
further confirm that changes in Reelin glycosylation can itself
be responsible of impaired Reelin signaling, we employed also
a different strategy to modify Reelin glycosylation. SH-SY5Y
cells were treated with deoxymannojirimycin (DMJ), an inhibitor
of endoplasmic reticulum mannosidases and Golgi
mannosidase I. Neurons treated with altered Reelin glycoforms
induced by DMJ also fail to reduce tau phosphorylation (Figure
1). These results confirm that altered Reelin glycosylation
compromises its biological role of modulating tau
phosphorylation.
Reelin initiates a cytosolic kinase pathway which includes
phosphorylation of the Dab1 protein and phosphorylation of
GSK3β at serine 9, which suppresses its activity, preventing
hyperphosphorylation of tau [20]. Accordingly with the lack of
modulation of tau phosphorylation, neurons treated with Aβ-
Reelin show a decrease in phosphorylation of Dab1, as well as
in phosphorylation of GSK3β at serine 9 (Figure 2).
Involvement of the protein 14-3-3 in the Aβ-Reelin
signaling
Tau and GSK3β form a complex where 14-3-3, a phospho-
serine binding protein, may play a role by acting as bridge
between these proteins. The 14-3-3 protein enhances tau
phosphorylation by GSK3β favoring that GSK3β
phosphorylated at serine 9 remains active and phosphorylates
tau [21,22]. We have observed that the levels of 14-3-3 are
Figure 1.  Aβ-Reelin fails to reduce tau phosphorylation.  Levels of phospho-tau (P-tau; antibodies AT8 and PHF13) and total
tau were calculated in primary mouse cortical neuron cultures treated with similar amounts of Reelin obtained from SH-SY5Y cells
treated with 0 (control, C-Reel), 1 or 10 µM of Aβ42 (Aβ-Reel), or scrambled Aβ42 peptide (Aβsc-Reel; 10 µM) (at least n= 6, from 3
independent experiments). The comparison with non-treated cultures (No Reel) is also shown. In some experiments Cont-Reelin
was pre-incubated with the antibody CR50 (15 µg/ml) for 1 h prior to treatment (n=3). Neuronal cultures were also incubated with
Reelin glycoforms obtained from SH-SY5Y cells treated with 0 (control, C-Reel) or 100 µM of the mannosidase inhibitor DMJ (DMJ-
Reel) (n= 6, from 2 independent experiments). The data represent the percentages of variation (means ± SEM) with respect to
values determined for C-Reel treated cells. Data were analyzed using ANOVA analysis of variance, followed by Tukey test to
compare all groups. *Significantly different (p < 0.05) from C-Reel treated cells.
doi: 10.1371/journal.pone.0072297.g001
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significantly higher in cells treated with Aβ-Reelin compared to
Cont-Reelin (Figure 3). Interestingly, neurons treated with Aβ-
Reelin display similar 14-3-3 levels to those treated with the
antibody CR50, which inhibits Reelin function. Our data
indicate that 14-3-3 could be part of the Reelin signaling
pathway, and suggests that this mechanism is also affected by
the impaired Reelin signaling, and may contribute to the
increment of tau phosphorylation.
Aβ-induced Reelin species fail to form physiologically
active dimers and bind less efficiently to ApoER2
Reelin dimer formation is required for the full biological
activity of the protein and to transduce its signaling [23,24].
Secreted disulfide-linked homodimer of Reelin are the forms
found in vivo in brain and plasma [14,25,26]. Non-covalent
(mainly electrostatic) interactions, also participate in the
formation of functional Reelin dimers; but large complexes
based only in electrostatic interactions fail to transduce
signaling [24,25]. Thus, we next analyzed if the ability of Reelin
to dimerize is affected when the protein is expressed in
presence of Aβ. Supernatants containing Cont-Reelin or Aβ-
Figure 2.  Aβ-Reelin fails to induce phosphorylation of
Dab1 and GSK3β.  Total cell lysates from primary mouse
cortical neuron cultures treated without Reelin (No Reel) or with
similar amounts of Reelin obtained from SH-SY5Y cells treated
with 0 (control, C-Reel) or 10 µM of Aβ42 (Aβ-Reel) were
probed with antibodies specific for total Dab1 and anti-
phosphotyrosine Dab1 (P-Dab1), and GSK3β phosphorylated
at serine 9 and total GSK3β. Levels of phosphorylated Dab1,
GSK3β and tau were normalized to total Dab1, and GSK3β
levels and tau respectively (n= 5 independent experiments for
Dab1, GSK3β; n= 3 independent experiments for CR50). Data
(means ± SEM) were analyzed using ANOVA analysis of
variance, followed by Tukey test to compare all groups.
*Significantly different (p < 0.05) from C-Reel treated cells.
doi: 10.1371/journal.pone.0072297.g002
Reelin were prepared for Western blotting in the presence and
absence of SDS and β-mercaptoethanol in the sample buffer
during the denaturation step, and then, both the stacking and
resolving gel were examined. When disulfide bonds were not
reduced Cont-Reelin failed to enter the SDS-PAGE resolving
gel and most material remained at the top of the stacking gel;
while Aβ-Reelin was resolved as monomer bands of 420, 310
and 180 kDa (Figure 4A), indicating that Reelin present in AD
brain may not have capacity to form covalent dimers. Previous
studies have also used a cell adhesion assay to demonstrate
Reelin homophilic interaction [25]. In our experiments, cells
plated in dishes coated previously with Aβ-Reelin attach in a
lesser number than when dishes are coated with Cont-Reelin,
indicating an impaired homophilic interaction for abnormal
Reelin (Figure S2). Altogether, these results indicate that
covalent dimerization is impaired in Aβ-Reelin.
We also examined if failure of Reelin to form dimers affects
its capacity to bind ApoER2. This Reelin-ApoER2 interaction
was examined by an ApoER2 binding assay using recombinant
ApoER2. While both Aβ-Reelin and Cont-Reelin were able to
bind recombinant ApoER2, Aβ-Reelin had decreased binding
capacity (Figure 4B).
Reelin from AD brain fails to form physiologically
active dimers
While several studies have determined Reelin levels in AD
brain and CSF, Reelin functionality has not been determined.
Therefore, we examined Reelin isolated from the frontal cortex
of AD subjects by blue native-PAGE to determine if these form
homodimers or instead form larger inactive complexes.
Complexes were extracted in assay buffer containing 0.5%
DDM [27]. In ND (non-demented) brain extracts, as expected, a
band was identified at ~450 kDa, representing the full-length
protein, together with a high molecular mass band of ~800 kDa,
probably corresponding to dimers of Reelin (Figure 5A).
However, in the AD brain Reelin complexes appeared from
Figure 3.  Increased 14-3-3 levels in neurons treated with
Aβ-Reelin.  Primary neurons were treated without Reelin (No
Reel) or with Cont-Reelin (C-Reel) or Aβ-Reelin (Aβ-Reel), or
Cont-Reelin pre-incubated with the antibody CR50 as
described in Figure 1; and cell lysates were probed for 14-3-3
and normalized respect to total tau levels (n=3 independent
experiments, values are means ± SEM). *Significantly different
(p < 0.05) from C-Reel treated cells.
doi: 10.1371/journal.pone.0072297.g003
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~450 to ~1400 kDa, with several Reelin immunoreactive bands
corresponding to intermediates and large complexes (Figure
5A).
The Reelin complexes were further characterized by
sedimentation analysis. Triton X-100/Nonidet P-40 extracts
from the frontal cortex of AD and ND subjects were also
fractionated on sucrose density gradients and resolved by
Western blotted under denaturing conditions in order to
characterize the full-length 420 kDa Reelin and the two N-
terminal 310 and 180-kDa fragments. Reelin from AD extracts
sediments in denser fractions than Reelin from ND extracts
(Figure 5B). In the AD brain, Reelin forms complexes of higher
Figure 4.  β-Amyloid compromises Reelin dimerization and affinity for ApoER2.  (A) Aβ-induced Reelin cannot form covalent
homodimers. Cont-Reelin or Aβ-Reelin glycoforms were denatured in the presence or absence of SDS/β-mercaptoethanol (βME)
and subjected to SDS-PAGE followed by immunoblotting with anti-Reelin antibody (representative blots from 4 different experiments
are shown). (B) Immobilized ApoER2 was incubated with enriched soluble-Reelin supernatant obtained from untransfected SH-
SY5Y cells treated with 0 (control, C-Reel) or 10 µM Reelin (Aβ-Reel), and the precipitated protein (IP or bound) fractions were
assessed by immunoblotting with an anti-Reelin antibody. The average percentage of the 420-kDa Reelin binding to immobilized
ApoER2, expressed as mean± SEM of 4 independent determinations, is shown. Reelin which did not bind to ApoER2 (unb) is also
shown. t-Test; *p< 0.05.
doi: 10.1371/journal.pone.0072297.g004
Figure 5.  Reelin from AD cortex form large complexes.  (A) Brain Reelin complexes from frontal cortex of ND and AD subjects
(extracted in buffer containing 0.5% DDM) were analyzed by blue native-PAGE. * Asterisks indicate presence of intermediate and
large Reelin complexes in AD samples. (B) Reelin extracted from frontal cortex of the same ND and AD subjects in presence of
Triton X-100/Nonidet P-40 were applied to 5-20% sucrose density gradients (fractions were collected from the bottom of each tube).
Aliquots from odd numbered fractions were immunoblotted for Reelin under denaturing conditions with the anti N-terminal Reelin
antibody 142, which allows identification of the full-length 420 kDa Reelin and the two N-terminal 310 and 180-kDa fragments.
Enzymes of known sedimentation coefficient, β-galactosidase (G, 16.0S; MW~ 540 kDa), catalase (C, 11.4S; MW~ 232 kDa) and
alkaline phosphatase (P, 6.1S; MW ~ 140-160 kDa) were used as internal markers. (C) The same brain extracts were analyzed by
lectin binding using Con A and LCA. The unbound Reelin glycoforms were determined by Western blotting (right panels).
Representative cases from five independent experiments are shown.
doi: 10.1371/journal.pone.0072297.g005
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molecular mass than the functional homodimers present in the
non-pathological condition, and this could lead to an impaired
capacity to bind correctly to its receptor. We have previously
demonstrated altered Reelin expression as the result of an
altered glycosylation pattern of the protein in the AD frontal
cortex [10,11]. We corroborated that Reelin glycoforms
extracted from ND brain cortex bind strongly to Con A than to
LCA (decreased Reelin immunoreactivity); whereas in AD
samples Reelin glycoforms have similar or higher affinity for
LCA compared to Con A (Figure 5C).
Discussion
Levels of Reelin in AD cortex have been analyzed due to its
important role in modulation of synaptic transmission and tau
hyperphosphorylation, both significantly altered in this disease.
An efficient Reelin signaling cascade controls tau
phosphorylation, thus a reduction in Reelin may favor
progression of the disease. However, Aβ treatment elevates
Reelin levels and alters its glycosylation [11]. The
physiopathological significance of an increased expression of
altered species of Reelin in affected brain regions from AD
patients remains unclear; and evaluation of its levels by
Western blotting or immunohistochemistry alone, will not
determine the correct function of the protein. Our present
results indicate that Aβ compromises Reelin biological function
by altering binding affinities to its receptor. Therefore, in spite
of potential increased levels of the protein, this Reelin should
result nonfunctional and Reelin signaling ends impaired in the
AD brain.
Our data indicate that Reelin present in AD brain it is not
capable of forming active homodimers. The possibility that
Reelin binds to itself was proposed [25], and demonstrated in
vivo [14,26]. Indeed, covalent homodimers of Reelin are the
functional units which interact with receptors [23]. The covalent
bond could be via a unique cysteine residue in the central
region of Reelin [24]. N-terminal Reelin fragments form large
but unstable assemblies that do not induce efficient
phosphorylation of Dab1 [26]. The sedimentation analysis
demonstrates differences between Reelin species extracted
from AD and ND brains. Changes in glycosylation
characterized in Reelin extracted from AD brain may result in
abnormal homophilic interaction of altered Reelin glycoforms
forming inactive high molecular mass complexes. Changes in
glycosylation may also affect Reelin/ApoER2 interactions.
Our data indicate that abnormal Reelin species, triggered by
Aβ treatment, are inefficient in activating the signaling cascade
and in controlling tau phosphorylation. Abnormal Reelin
species fail to form active dimers and to bind properly to
ApoER2. Interestingly, aberrant Reelin present in the AD brain
form large complexes instead of dimers. Thus, abnormal Reelin
species may interact with normal forms of the protein, possibly
sequestering these to form oligomeric complexes but not
physiologically active dimers (Figure 6). Therefore, despite an
increase in the total amount of Reelin in the AD brain, less
active Reelin may be available. We have also reported in the
Tg2576 APP mice increased levels of Reelin [11]. In view of
our present results the amount of active (dimers) and inactive
(large complexes) Reelin should be analyze in this and others
mice models of Aβ over-expression. Furthermore, an increase
in abnormal Reelin would result in less activation of the Reelin
signaling pathway and could contribute to the generation of a
vicious cycle, where Reelin up-regulation may be driven by a
chronic failure in Reelin signaling. Up-regulation of proteins in
response to chronic inhibition is a recognized phenomenon
documented for several proteins [28–30].
Alternative consequences for the lack of modulation of tau
phosphorylation by Aβ-Reelin signaling have also been
considered. We have demonstrated that neurons treated with
Aβ-Reelin display an increase in the scaffold protein 14-3-3, a
protein that only when is present maintains GSK3β
phosphorylated at serine 9 active and this phosphorylates tau
[22]. Whether changes in 14-3-3 levels are part of a
compensatory system of the complex tau-GSK3β to regulate
GSK3β activity, or directly respond to Reelin signaling through
ApoER2 or other receptors remain to be elucidated (Figure 6).
Interestingly, it has been shown in platelets that 14-3-3 is
translocated to the cytoskeleton after ApoER2 activation [31].
Moreover, Reelin coreceptors, members of the family of
cadherin-related neuronal receptors (CNRs) [32] or integrins
[33] have been proposed to be involved in the Reelin pathway;
however it has also been demonstrated that Reelin binding to
ApoER2 itself seems to be sufficient to transmit the signal and
does not appear to require any other coreceptor [23]. However,
we cannot exclude that such coreceptors participate in other
cellular events induced by Reelin binding, including regulation
of the 14-3-3 protein. Indeed, 14-3-3 levels can be modulated
by integrins [34]. Furthermore, several isoforms of 14-3-3 have
been found to be increased in the brains of patients with AD
[35], and a recent proteomic approach confirms that 14-3-3 can
be a disease-specific protein in AD [36]. Our data indicate that
intracellular 14-3-3 levels are similar in cultures treated with
either altered glycoforms of Reelin or with Reelin blocked by
the CR50 antibody, demonstrating further that altered Reelin
glycoforms may sequester active Reelin.
Our previous studies illustrated altered Reelin glycosylation
in cells treated with Aβ using immobilized Con A and LCA and
a LCA gel-shift assay [11]. Abnormal Reelin species also
resemble Reelin detected in the AD brain in altered
glycosylation pattern. We have no direct evidence that Aβ
mediates changes in Reelin glycosylation compromise Reelin
functionality, since it is likely that other cellular components are
present in our Reelin-enriched fractions, and particularly Aβ.
Similarly, we presume that oligomeric Aβ is the specie that
affects the glycosylation of Reelin; however, under the
conditions of our cellular experiments, we cannot differentiate if
this effect is due to monomeric, oligomeric Aβ or fibers.
Moreover, it is possible that Aβ itself adversely affects Reelin
signaling (Figure 6). Further studies addressing the possibility
that Aβ (monomers or oligomers) interacts directly with Reelin
are warranted. Nonetheless, an impaired ability of Reelin to
modulate tau phosphorylation was also exhibited by altered
Reelin glycoforms induced by DMJ, an inhibitor of
mannosidase. Thus, we favor the hypothesis that alterations in
Reelin glycosylation affect the ability to form active dimers, bind
the receptor and control the extent to which the tau protein is
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phosphorylated. Discrete changes in the glycosylation profile of
key brain proteins could have a critical impact in their function.
Indeed, APP (the amyloid-precursor protein) glycosylation can
modulate its metabolic turnover [37]. Glycosylation also
modulates the function of β-secretase [38] and γ-secretase
[39], and the processing of ApoER2 by γ-secretase [40]. In
addition, glycosylation has been shown to play a role in
modulating the hyperphosphorylation status of tau [41] and the
maintenance of paired helical filaments [42]. The physiological
relevance of the change in the glycosylation profile for key AD
proteins including Reelin is clear; however the mechanism
through which Aβ affects the glycosylation of Reelin warrants
further study.
In conclusion, we present evidence of the abnormal
dimerization of Reelin in the AD brain which suggests an
altered signaling in vivo. We have shown that Aβ induces
expression of abnormal (non physiologically efficient) Reelin
species, resulting in impaired Reelin signaling. Our data
associates Aβ and tau phosphorylation dysregulation through
Reelin and raises the possibility that Reelin directly contributes
to the progress of AD pathology.
Supporting Information
Figure S1.  Aβ42 induces changes in secreted Reelin from
cultured cells.
(A) Aβ content was measured in the cell medium from non-
treated (NT) or Aβ-treated SH-SY5Y cells before and after
preparation procedures, and compared with the amount found
in the pellet of the cell medium obtained before filtration. The
Aβ was depleted of enriched Reelin fraction by filtration/
concentration (filtration) and alternatively by ulterior
immunoprecipitation (IP) with anti-Aβ antibody 6E10. There
was a neglected amount of the peptide in Reelin enriched
concentrates obtained from cell supernatants treated with 1 µM
Aβ42 (blot not shown). Positions of the molecular-weight (MW)
markers are shown. There was no significant cell death in
cultures treated with 10 µM Aβ42, as evaluated by the MTS
assay (13 ±5% reduction, p= 0.2), and only marginal cell death
was estimated in cells treated with 10 µM Aβ42 (28 ±4%
reduction, p= 0.008). (B) The glycosylation status of secreted
Reelin from Aβ42-treated SH-SY5Y cells was analyzed by a
lectin-binding assay. Comparison of the pattern of unbound
Reelin to Con A or LCA are shown from representative cases
of Cont-Reelin (C-Reel) and Aβ-Reelin (Aβ-Reel)
(representative cases from 4 independent experiments are
shown).
(TIF)
Figure S2.  Impaired Reelin-mediated c capacity of Aβ-
Reelin.
Representative photographs of cells attached to a well coated
coated without Reelin (No Reel) or with Cont-Reelin (C-Reel),
Figure 6.  Schematic model of the impaired Reelin signaling in AD.  β-Amyloid triggers changes in Reelin glycosylation
impairing its ability to form active covalent homodimers. Accordingly, altered Reelin complexes display a reduced efficiency to bind
the ApoER2 receptor, fail to induce efficient tyrosine phosphorylation of Dab1, and to transduce the signaling pathway that
modulates tau phosphorylation by inhibition of GSK3β. Soluble Aβ can also contribute to the impaired ability of Reelin to activate its
signaling cascade. An imbalance in 14-3-3 levels is also triggered by the inefficient Reelin signaling.
doi: 10.1371/journal.pone.0072297.g006
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Aβ-Reelin (Aβ-Reel) or Cont-Reelin preincubated with CR50
antibody. The histogram shows the number of cells in each
case normalized to Cont-Reelin, which was scored as 100 (n=5
independent experiments, values are means ± SEM). t-Test *p
< 0.05, **p < 0.01.
(TIF)
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